By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
The Developing Nearby Food Development and Its Advantages - 2Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- 3Malaysia To Revive Search for Missing Flight MH370
- 4The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 5Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- 7 Odd Apparatuses to Make Your Party Stick Out!
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- The Way to Monetary Freedom: A Viable Aide
- Vote In favor of Your Favored Video Conferencing Administration
- NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
